Ovid Therapeutics
OVIDOvid Therapeutics is a biopharmaceutical company focused on developing first-in-class or best-in-class small molecule medicines for central nervous system (CNS) disorders.
Earnings
Q2 2026 report
August 13, 2026Next report
Nov 11, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Ovid Therapeutics is a biopharmaceutical company focused on developing first-in-class or best-in-class small molecule medicines for central nervous system (CNS) disorders. The company targets fundamental biological mechanisms, such as neurotransmitters and dysregulated ion channels, to mitigate neuronal hyperexcitation. Its core value proposition lies in addressing significant unmet needs in epilepsy, psychosis, and neurodegenerative conditions through differentiated mechanisms of action.
Ovid positions itself as a specialist in neuronal hyperexcitability, leveraging novel mechanisms of action to compete in high-value CNS markets where current standards of care are often inadequate or poorly tolerated.
FAQ
- What is Ovid Therapeutics's market cap?
- Ovid Therapeutics (OVID) has a market capitalization of $500.0M and trades on NASDAQ.
- Who are Ovid Therapeutics's competitors?
- Ovid Therapeutics's key competitors include Acadia Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences, and others. These companies compete in similar markets and product categories.
- Who does Ovid Therapeutics partner with?
- Ovid Therapeutics's notable partners include Takeda Pharmaceutical Company, AstraZeneca.
- Where is Ovid Therapeutics headquartered?
- Ovid Therapeutics is headquartered in United States of America and employs approximately 40 people. It has been publicly traded since 2017.